FTI Advances is India's specialist OEL services provider — delivering occupational exposure limit calculations, OEB banding, and worker safety documentation for HPAPIs, oncology drugs, hormones, and cytotoxics.
An Occupational Exposure Limit (OEL) is the maximum permissible airborne concentration of an active pharmaceutical ingredient (API) that workers can be exposed to during an 8-hour workday without adverse health effects. Unlike the ADE/PDE — which protects patients from cross-contamination — the OEL protects manufacturing personnel who handle, weigh, dispense, and process APIs during production operations.
Regulatory bodies and industry guidelines including EMA, OSHA (29 CFR 1910.1000), ACGIH TLVs, NIOSH RELs, and ISPE SMEPAC all require documented OEL values for potent pharmaceutical compounds. In India, the revised Schedule M cGMP aligns with these international expectations, requiring worker safety documentation for HPAPI manufacturing.
Without a properly derived OEL from a qualified OEL services provider, pharmaceutical facilities cannot make evidence-based decisions on engineering controls, personal protective equipment (PPE), containment technology, or occupational health monitoring programmes.
As an experienced OEL value services provider, FTI Advances follows a rigorous, internationally recognised OEL derivation process. Each assessment involves a systematic literature review across PubMed, ECHA, ToxNet, FDA submission databases, and proprietary toxicological sources to identify all available pharmacological and toxicological data for the target compound.
The critical toxicological effect — the most sensitive endpoint in the most sensitive species — is identified and a Point of Departure (POD) established, typically as a NOAEL (No Observed Adverse Effect Level) or LOAEL (Lowest Observed Adverse Effect Level). Where animal data is used, interspecies correction factors and intraspecies variability factors are applied. Additional modifying factors account for route-to-route correction (oral to inhalation), time-weighted average adjustments, and residual data uncertainty.
The final OEL is expressed as an 8-hour TWA airborne concentration in µg/m³, with supporting OEB classification and engineering control recommendations.
For novel APIs or compounds with incomplete toxicological datasets, Occupational Exposure Banding (OEB) provides a rapid, risk-based classification framework. OEB assigns compounds to bands (typically OEB 1 through OEB 5) based on their hazard profile — guiding immediate decisions on containment, PPE, and facility design before full quantitative OEL derivation is completed.
FTI Advances provides both preliminary OEB banding (for early-stage compounds or rapid risk assessment) and full quantitative OEL derivation (for established APIs requiring regulatory-grade worker safety documentation). Our OEB classifications are structured per ISPE SMEPAC guidelines and are compatible with all major containment category frameworks used by pharmaceutical isolator and containment equipment manufacturers.
The pharmaceutical industry's shift towards oncology therapeutics, hormone-based drugs, and targeted small molecules has dramatically increased the volume of HPAPI (Highly Potent Active Pharmaceutical Ingredient) handling in manufacturing facilities. HPAPIs typically fall in OEB 4 or OEB 5 — requiring fully enclosed isolators, HEPA-filtered air handling, and specialised decontamination protocols.
FTI Advances specialises in OEL and OEB derivation for the following compound categories: oncology APIs (cytotoxic, targeted therapies), hormones and steroids (oestrogens, progestogens, androgens, corticosteroids), immunosuppressants, antifungals, highly potent cardiovascular drugs, biologics and biosimilars with occupational exposure concerns, and novel investigational compounds (NCEs and NBEs) in early development phases.
For each of these categories, our qualified toxicologists apply compound class-specific methodological considerations — including pharmacological potency correction, reproductive and developmental toxicity weighting, and sensitisation potential assessment.
Every OEL report from FTI Advances as your OEL value services provider includes the following components: structured literature search documentation with database coverage and search strategy; complete toxicological data tables with study type, species, dose, and observed effects; critical effect identification and POD selection with scientific justification; uncertainty factor application with individual rationale for each factor; final OEL value calculation with units (µg/m³ and µg/cm² surface limit); OEB classification per ISPE SMEPAC framework; recommended engineering controls and PPE by containment category; and the qualified toxicologist's credentials and declaration of independence.
Reports are delivered in audit-ready PDF and Word format, with a complete data package suitable for your supplier qualification file — meeting EMA Chapter 7 requirements for contracted HBEL services.
As an Indian CRO incubated at the National Forensic Sciences University (NFSU), Ahmedabad, FTI Advances combines world-class toxicological expertise with cost-effective pricing, fast turnaround, and dedicated client support. Our OEL services are used by pharmaceutical manufacturers across India, the USA, Europe, and Southeast Asia — from multinational API producers to emerging biotech companies handling novel HPAPIs.
We offer integrated ADE/PDE + OEL packages, allowing manufacturers to source both patient safety and worker safety HBEL documentation from a single OEL value services provider — simplifying supplier qualification, reducing administrative overhead, and ensuring scientific consistency between your cleaning validation limits and occupational safety programme.
FTI Advances provides complete OEL calculation india services for pharmaceutical manufacturers of all sizes. Our OEL calculation methodology covers all potent compound categories — from HPAPI OEL services India for oncology and cytotoxic APIs to OEL derivation for hormones, steroids, immunosuppressants, and novel targeted therapies. We also perform preliminary OEL estimation for early-stage compounds where full datasets are not yet available.
As a trusted OEL value services provider for pharmaceutical manufacturers, we understand that speed and accuracy both matter. Our standard OEL calculation india turnaround is 5–7 business days, with expedited 48-hour service for urgent containment strategy decisions. Every OEL report includes surface contamination limits (µg/cm²) in addition to airborne limits (µg/m³) — giving your industrial hygiene team everything needed to validate cleaning procedures and set wipe sampling acceptance criteria for potent compound handling areas.
FTI Advances also supports OEB to OEL transition — where a compound initially classified by OEB banding subsequently requires a full quantitative OEL as manufacturing scale-up progresses. Our integrated approach ensures scientific consistency between the preliminary OEB classification and the final OEL value, avoiding contradictory documentation in your regulatory files.
Reputation in the regulated pharmaceutical industry is built on outcomes — and FTI Advances has earned its position as a trusted OEL value services provider by consistently delivering occupational exposure limit reports that stand up to inspector scrutiny. Manufacturers across India, Europe, and the USA rely on our expertise because they know that every report is grounded in a thorough, up-to-date literature review, prepared by a credentialed toxicologist, and structured to meet the documentation expectations of EMA, OSHA, ACGIH, and ISPE SMEPAC simultaneously. This focus on quality makes FTI Advances the natural choice when worker safety and regulatory compliance are equally important.
A high-quality OEL assessment is more than a number on a page. It is a documented scientific argument — one that a regulatory inspector or industrial hygienist can follow from raw toxicological data to a final airborne exposure limit. At FTI Advances, every engagement as an OEL value services provider follows this standard: the critical toxicological endpoint is clearly identified, the point of departure is selected and justified, each uncertainty factor is applied with an individual rationale, and the final OEL value is expressed with supporting engineering control and containment recommendations. This level of documentation transparency is what separates a defensible OEL report from a generic template — and it is what our clients rely on when preparing for EMA or USFDA GMP inspections.
Pharmaceutical manufacturing encompasses an enormous diversity of molecular types, each presenting unique challenges for occupational exposure assessment. FTI Advances has extensive experience across all of them. For well-characterised small molecule APIs, our standard OEL value services provider methodology applies straightforwardly. For novel HPAPIs with limited preclinical data, our toxicologists employ read-across from structurally related compounds, structural alert analysis, and pharmacological potency-based estimation — producing a scientifically justified OEL value even under data-limited conditions. This capability ensures that your containment strategy is always grounded in the best available evidence, regardless of how early or complex your compound may be.
Submit your API for occupational exposure limit derivation. Reports accepted by EMA, OSHA, and WHO inspectors — delivered in 5–7 business days.
Request OEL Assessment →Comprehensive worker safety documentation from India's specialist OEL value services provider.
Quantitative 8-hour TWA occupational exposure limit with complete data package and regulatory citations.
Rapid occupational exposure banding (OEB 1–5) for novel or early-stage APIs per ISPE SMEPAC guidelines.
Specialised OEL assessment for highly potent APIs, cytotoxics, hormones, and oncology compounds.
Combined patient safety (ADE/PDE) and worker safety (OEL) HBEL package from one provider.
Engineering control and PPE recommendations based on OEB classification and compound potency.
Scheduled review of existing OEL values with updated literature search — per EMA Q&A 2018 requirements.
ADE/PDE protects patients from cross-contamination of APIs in shared manufacturing equipment. OEL protects workers from airborne API exposure during manufacturing operations. Both are derived by qualified toxicologists using similar methodology but with different exposure scenarios and adjustment factors.
Any pharmaceutical facility handling potent APIs, HPAPIs, cytotoxics, hormones, or novel compounds requires an OEL to implement appropriate engineering controls and PPE. This is required by EMA, OSHA, ACGIH, and India's revised Schedule M for HPAPI manufacturers.
Yes. For investigational new drugs (INDs) or compounds with limited toxicological data, FTI Advances provides preliminary OEB classification using read-across methodology, structural alerts, pharmacological class analysis, and expert toxicologist judgment — giving immediate guidance for containment decisions.
The OEL is typically expressed as an 8-hour TWA concentration in µg/m³. It is used to select appropriate containment technology (open dispensing, downflow booths, RABS, or isolators), determine PPE requirements, set industrial hygiene monitoring thresholds, and design occupational health surveillance programmes.
OEL reports aligned with